Loading...
Market
What will be Novo Nordisk's market position in the obesity drug sector by the end of 2025?
2
Resolution / Starting Odds
Leader in the sector • 25%
Top 3 in the sector • 25%
Top 5 in the sector • 25%
Outside top 5 • 25%
Market analysis reports from reputable financial and market research firms
Story
Novo Nordisk Shares Plunge 29% After CagriSema Falls Short of 25% Weight Loss Target
Dec 20, 2024, 12:30 PM
Novo Nordisk announced that its experimental obesity drug CagriSema achieved a 22.7% weight loss in adults with obesity or overweight in the REDEFINE 1 Phase 3 trial after 68 weeks. While this result demonstrated superior weight loss compared to semaglutide 2.4 mg (16.1%), cagrilintide 2.4 mg (11.8%), and placebo (2.3%), it fell short of the company's anticipated target of 25% weight loss. Following the announcement, Novo Nordisk's shares plunged as much as 29%, marking the largest single-day drop on record for the company and erasing over $140 billion in market value.
View original story
Similar markets
More than 50% • 25%
30% to 40% • 25%
40% to 50% • 25%
Less than 30% • 25%
Eli Lilly > 60% • 25%
Novo Nordisk > 60% • 25%
Novo Nordisk 40-60% • 25%
Eli Lilly 40-60% • 25%
Eli Lilly • 25%
Other • 25%
Pfizer • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
Novo Nordisk • 25%
No major announcement • 25%
Partnership with another company • 25%
New drug entering Phase 3 trials • 25%
Improved results for CagriSema • 25%
Below Top 20 • 25%
Top 10 • 25%
Top 20 • 25%
Top 5 • 25%
Kidney disease • 25%
Stroke • 25%
Heart disease • 25%
Brain disorders • 25%
Trial cancelled • 25%
Falls short of expectations • 25%
Meets expectations • 25%
Exceeds expectations • 25%
Wegovy • 25%
Saxenda • 25%
Other • 25%
Zepbound • 25%
Viking Therapeutics • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Other • 25%